PT2639222T - Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos - Google Patents
Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicosInfo
- Publication number
- PT2639222T PT2639222T PT121965024T PT12196502T PT2639222T PT 2639222 T PT2639222 T PT 2639222T PT 121965024 T PT121965024 T PT 121965024T PT 12196502 T PT12196502 T PT 12196502T PT 2639222 T PT2639222 T PT 2639222T
- Authority
- PT
- Portugal
- Prior art keywords
- benzoic acids
- cycloalkylcarboxiamido
- producing
- pyridine benzoic
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1218107P | 2007-12-07 | 2007-12-07 | |
US10957308P | 2008-10-30 | 2008-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2639222T true PT2639222T (pt) | 2016-11-01 |
Family
ID=40329178
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT121965024T PT2639222T (pt) | 2007-12-07 | 2008-12-04 | Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos |
PT88595822T PT2231606E (pt) | 2007-12-07 | 2008-12-04 | Processos para a produção de ácidos cicloalquilcarboxiamido-piridina benzóicos |
PT121965396T PT2639224T (pt) | 2007-12-07 | 2008-12-04 | Processos para produzir ácidos benzoicos cicloalquilcarboxamida-piridina |
PT121965115T PT2639223T (pt) | 2007-12-07 | 2008-12-04 | Processos para produção de ácidos cicloalquilcarboxamido-piridinabenzoicos |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT88595822T PT2231606E (pt) | 2007-12-07 | 2008-12-04 | Processos para a produção de ácidos cicloalquilcarboxiamido-piridina benzóicos |
PT121965396T PT2639224T (pt) | 2007-12-07 | 2008-12-04 | Processos para produzir ácidos benzoicos cicloalquilcarboxamida-piridina |
PT121965115T PT2639223T (pt) | 2007-12-07 | 2008-12-04 | Processos para produção de ácidos cicloalquilcarboxamido-piridinabenzoicos |
Country Status (26)
Country | Link |
---|---|
US (4) | US8124781B2 (pt) |
EP (4) | EP2639223B1 (pt) |
JP (4) | JP5702149B2 (pt) |
KR (3) | KR20150066608A (pt) |
CN (2) | CN101910134B (pt) |
AU (1) | AU2008335440B2 (pt) |
BR (1) | BRPI0820902A2 (pt) |
CA (3) | CA2707494C (pt) |
CL (1) | CL2010000631A1 (pt) |
CY (4) | CY1113985T1 (pt) |
DK (4) | DK2639223T3 (pt) |
EA (1) | EA201070700A1 (pt) |
ES (4) | ES2604178T3 (pt) |
HK (2) | HK1146820A1 (pt) |
HR (4) | HRP20130418T1 (pt) |
HU (3) | HUE029775T2 (pt) |
IL (4) | IL206205A (pt) |
LT (3) | LT2639223T (pt) |
MX (4) | MX364935B (pt) |
NZ (3) | NZ612635A (pt) |
PL (4) | PL2231606T3 (pt) |
PT (4) | PT2639222T (pt) |
RS (4) | RS55360B1 (pt) |
SI (4) | SI2639223T1 (pt) |
WO (1) | WO2009076142A2 (pt) |
ZA (1) | ZA201003624B (pt) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
WO2005026137A2 (en) | 2003-09-06 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
EP2140865A1 (en) * | 2003-11-14 | 2010-01-06 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
CA2571949C (en) | 2004-06-24 | 2015-05-12 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
MX2008002019A (es) | 2005-08-11 | 2008-04-16 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
CN102775396B (zh) * | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合***转运蛋白的杂环调控剂 |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
HUE049976T2 (hu) | 2005-12-28 | 2020-11-30 | Vertex Pharma | N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói |
US7691902B2 (en) | 2005-12-28 | 2010-04-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7776905B2 (en) | 2006-04-07 | 2010-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) * | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
NZ581309A (en) * | 2007-05-25 | 2012-02-24 | Vertex Pharma | Ion channel modulators and methods of use |
ES2578735T3 (es) | 2007-08-24 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística |
SI2578571T1 (sl) | 2007-11-16 | 2016-01-29 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto |
ES2790830T3 (es) * | 2007-12-07 | 2020-10-29 | Vertex Pharma | Formas solidas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico |
DK2639223T3 (en) | 2007-12-07 | 2017-06-19 | Vertex Pharma | Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids |
UA95199C2 (en) * | 2007-12-07 | 2011-07-11 | Вертекс Фармасьютикалз Инкорпорейтед | Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
US20100036130A1 (en) * | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
NZ703814A (en) | 2008-02-28 | 2016-06-24 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
CN101981011B (zh) | 2008-03-31 | 2014-05-07 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的吡啶基衍生物 |
CN102164587A (zh) | 2008-09-29 | 2011-08-24 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元 |
PL2349263T3 (pl) | 2008-10-23 | 2014-11-28 | Vertex Pharma | Modulatory mukowiscydozowego regulatora przewodnictwa przezbłonowego |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
NZ708598A (en) | 2010-04-07 | 2017-05-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d](1,3)dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
TWI549950B (zh) | 2010-04-07 | 2016-09-21 | 維泰克斯製藥公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧雜環戊烯-5-基)環丙烷甲醯胺基)-3-甲基吡啶-2-基)苯甲酸之固體形式 |
EP3045452A1 (en) | 2010-04-22 | 2016-07-20 | Vertex Pharmaceuticals Inc. | Process of producing cycloalkylcarboxamido-indole compounds |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
IN2014KN00885A (pt) | 2011-11-08 | 2015-10-02 | Vertex Pharma | |
MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
WO2014160440A1 (en) | 2013-03-13 | 2014-10-02 | Flatley Discovery Lab | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
US10231932B2 (en) | 2013-11-12 | 2019-03-19 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
LT3925607T (lt) | 2014-04-15 | 2023-11-27 | Vertex Pharmaceuticals Incorporated | Farmacinė kompozicija, skirta gydyti ligas, kurias nulemia cistinės fibrozės transmembraninio laidumo reguliatorius |
GB201415381D0 (en) | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
WO2016057572A1 (en) | 2014-10-06 | 2016-04-14 | Mark Thomas Miller | Modulators of cystic fibrosis transmembrane conductance regulator |
JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
WO2016081556A1 (en) | 2014-11-18 | 2016-05-26 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
US10512636B2 (en) * | 2015-05-29 | 2019-12-24 | Emory University | 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases |
EP3804706B1 (en) | 2015-05-29 | 2023-08-23 | Emory University | 2-amino-n'-benzylideneacetohydrazides and derivatives for the management of cftr protein mediated diseases |
WO2017017696A1 (en) * | 2015-07-27 | 2017-02-02 | Mylan Laboratories Limited | Process for the preparation of lumacaftor |
CN105130949B (zh) * | 2015-09-02 | 2019-01-29 | 阜新奥瑞凯新材料有限公司 | 1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙基腈的制备方法 |
US10479782B2 (en) | 2015-09-29 | 2019-11-19 | Mylan Laboratories Limited | Forms of lumacaftor and processes for the preparation thereof |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
CN107033120B (zh) * | 2016-02-03 | 2020-03-17 | 苏州旺山旺水生物医药有限公司 | 2-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)乙氰的制备方法 |
WO2017137900A1 (en) | 2016-02-10 | 2017-08-17 | Lupin Limited | Amorphous lumacaftor and its solid dispersion |
DK3519401T3 (da) | 2016-09-30 | 2021-11-22 | Vertex Pharma | Modulator af cystisk fibrosetransmembrankonduktansregulator, farmaceutiske sammensætninger, fremgangsmåder til behandling og fremgangsmåde til fremstilling af modulatoren |
JOP20190125B1 (ar) | 2016-12-09 | 2022-03-14 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
WO2018107040A1 (en) * | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | 1-(2-fluorophenyl)-n-[1-(2-fluoro-4-pyridyl)pyrazol-3-yl]cyclopropanecarboxamide, its solid forms and pharmaceutical uses thereof |
UY37512A (es) * | 2016-12-09 | 2019-04-30 | Vertex Pharma | Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga |
MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2018309043B2 (en) | 2017-08-02 | 2022-03-31 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
GEP20237571B (en) | 2018-02-15 | 2023-11-27 | Vertex Pharma | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
JP2022544383A (ja) | 2019-08-14 | 2022-10-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrモジュレータの結晶形態 |
US20220313698A1 (en) | 2019-08-14 | 2022-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
CR20230197A (es) | 2020-10-07 | 2023-07-06 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
US20230416275A1 (en) | 2020-10-07 | 2023-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225446A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225750A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076622A2 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076620A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225737A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225764A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023196429A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
Family Cites Families (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3758475A (en) * | 1971-07-20 | 1973-09-11 | Sandoz Ag | Pyrido(2,3-d)pyrimidin 2 ones |
EP0081756B1 (en) | 1981-12-14 | 1985-05-15 | MEDEA RESEARCH S.r.l. | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions |
IT1226048B (it) | 1981-12-14 | 1990-12-10 | Medea Res Srl | Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative |
US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
US5981714A (en) | 1990-03-05 | 1999-11-09 | Genzyme Corporation | Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor |
JP3167762B2 (ja) * | 1990-11-27 | 2001-05-21 | 武田薬品工業株式会社 | ピリドピリダジン誘導体およびその用途 |
US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
CA2107196A1 (en) | 1992-09-29 | 1994-03-30 | Mitsubishi Chemical Corporation | Carboxamide derivatives |
GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
DE69416848T2 (de) * | 1993-10-21 | 1999-07-08 | G.D. Searle & Co., Chicago, Ill. | Amidino-derivate als no-synthetase inhibitoren |
DE4405712A1 (de) * | 1994-02-23 | 1995-08-24 | Basf Ag | Substituierte Naphthyridine und deren Verwendung |
RU2114844C1 (ru) * | 1994-04-11 | 1998-07-10 | Санкио Компани Лимитед | Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний |
BR9509036A (pt) | 1994-09-27 | 1997-10-14 | Janssen Pharmaceutica Nv | Derivados biciclicos de benzoato de peperidinila n-substituída |
US5656256A (en) | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
WO1997036871A1 (en) * | 1996-03-29 | 1997-10-09 | Pfizer Inc. | 6-phenylpyridyl-2-amine derivatives |
EP0891334A1 (en) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
DK0984778T3 (da) | 1996-08-23 | 2002-09-16 | Agouron Pharma | Neuropeptid-Y-ligander |
WO1998028980A1 (en) | 1996-12-30 | 1998-07-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5948814A (en) | 1997-02-20 | 1999-09-07 | The Curators Of The University Of Missouri | Genistein for the treatment of cystic fibrosis |
WO1998047868A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
ID24376A (id) * | 1997-10-02 | 2000-07-13 | Sankyo Co | Turunan-turunan asam amidokarboksilat |
AU2758899A (en) | 1998-02-17 | 1999-08-30 | G.D. Searle & Co. | Process for the enzymatic resolution of lactams |
MY133223A (en) | 1998-06-08 | 2007-10-31 | Schering Corp | Neuropeptide y5 receptor antagonists |
US6426331B1 (en) | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
IL142768A0 (en) | 1998-12-18 | 2002-03-10 | Du Pont Pharm Co | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
ATE280158T1 (de) | 1999-02-24 | 2004-11-15 | Hoffmann La Roche | 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten |
DK1394150T3 (da) | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
EP1157006B1 (en) | 1999-02-24 | 2006-10-25 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
WO2000078733A1 (de) | 1999-06-18 | 2000-12-28 | Bayer Aktiengesellschaft | Phenoxyfluorpyrimidine |
UA74539C2 (en) | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
WO2001046165A2 (en) | 1999-12-16 | 2001-06-28 | Novartis Ag | N-heteroaryl-amides and their use as parasiticides |
CA2396079A1 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
AU2001233069A1 (en) | 2000-01-28 | 2001-08-07 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
AU2001234689A1 (en) | 2000-02-01 | 2001-08-14 | Cor Therapeutics, Inc. | Bivalent phenylene inhibitors of factor xa |
AU2001249417A1 (en) | 2000-04-26 | 2001-11-07 | Gliatech, Inc. | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
WO2001083517A1 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Stat4 and stat6 binding dipeptide derivatives |
BR0106717A (pt) | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora |
TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
AU2001290914A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
JP4272338B2 (ja) * | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
AU2002211379A1 (en) | 2000-10-04 | 2002-04-15 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of cystic fibrosis |
GB2367816A (en) | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
EP1326854B1 (en) | 2000-10-20 | 2004-06-23 | MERCK PATENT GmbH | Chiral binaphthol derivatives |
US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
DE60142921D1 (de) * | 2000-12-01 | 2010-10-07 | Eisai Inc | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren |
JP2002197001A (ja) | 2000-12-27 | 2002-07-12 | Fujitsu Ltd | クライアント・サーバ型のシステムにおける情報の通信方法 |
GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US6531597B2 (en) | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
WO2003084997A1 (en) | 2001-04-10 | 2003-10-16 | Transtech Pharma, Inc. | Probes, systems and methods for drug discovery |
DK1385577T3 (da) | 2001-04-23 | 2006-08-21 | Hoffmann La Roche | Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi |
IL158958A0 (en) * | 2001-05-22 | 2004-05-12 | Neurogen Corp | 5-substituted-2-arylpyridines as crfi modulators |
JP2003015528A (ja) | 2001-06-28 | 2003-01-17 | Mint Bureau Ministry Of Finance | 画像表示構造 |
US20030083345A1 (en) | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
US20030144350A1 (en) | 2001-07-20 | 2003-07-31 | Adipogenix, Inc. | Fat accumulation-modulation compounds |
JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム (カナダ) リミテッド | ウイルスポリメラーゼインヒビター |
WO2003022852A2 (en) | 2001-09-11 | 2003-03-20 | Smithkline Beecham Corporation | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
JP2003221386A (ja) * | 2001-11-26 | 2003-08-05 | Takeda Chem Ind Ltd | 二環性誘導体、その製造法およびその用途 |
EP2305648A1 (en) | 2001-12-21 | 2011-04-06 | Novo Nordisk A/S | Amide derivatives useful as glucokinase activators |
TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
GB0221443D0 (en) * | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
AU2003287160A1 (en) | 2002-10-15 | 2004-05-04 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
US7514431B2 (en) | 2002-10-30 | 2009-04-07 | Merck & Co., Inc. | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity |
CA2508780A1 (en) | 2002-12-12 | 2004-07-01 | Pharmacia Corporation | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
US7576108B2 (en) | 2003-01-06 | 2009-08-18 | Eli Lilly And Company | Substituted arylcyclopropylacetamides as glucokinase activators |
CA2755297A1 (en) * | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
EP1601657A1 (en) | 2003-03-12 | 2005-12-07 | Vertex Pharmaceuticals Incorporated | Pyrazole modulators of atp-binding cassette transporters |
EP1620420A2 (en) | 2003-04-30 | 2006-02-01 | The Institutes for Pharmaceutical Discovery, LLC | Substituted carboxylic acids |
WO2004111014A1 (en) | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
ATE554766T1 (de) | 2003-06-27 | 2012-05-15 | Jackson H M Found Military Med | Amphiphile pyridinium-verbindungen, herstellungsverfahren und ihre verwendung |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
JP2005053902A (ja) * | 2003-07-18 | 2005-03-03 | Nippon Nohyaku Co Ltd | フェニルピリジン類、その中間体及びこれを有効成分とする除草剤 |
EP1680424A2 (en) * | 2003-09-05 | 2006-07-19 | Neurogen Corporation | Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands |
WO2005026137A2 (en) | 2003-09-06 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
WO2005035514A2 (en) | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
FR2861304B1 (fr) * | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | Modulateurs des canaux cftr |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
EP2140865A1 (en) | 2003-11-14 | 2010-01-06 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
JP2007511572A (ja) * | 2003-11-19 | 2007-05-10 | グラクソ グループ リミテッド | 統合失調症治療のためのシクロオキシゲナーゼ−2選択的阻害剤の使用 |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
AU2005210474B2 (en) | 2004-01-30 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
JPWO2005080348A1 (ja) * | 2004-02-19 | 2007-08-02 | 萬有製薬株式会社 | 新規スルホンアミド誘導体 |
ES2241496B1 (es) * | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
EP1734820A4 (en) * | 2004-04-16 | 2008-01-23 | Neurogen Corp | Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands |
US7585885B2 (en) * | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
JP2007533740A (ja) * | 2004-04-22 | 2007-11-22 | イーライ リリー アンド カンパニー | Bace阻害剤としてのアミド |
US20080138803A1 (en) | 2004-06-01 | 2008-06-12 | Galvan-Goldman Nee Galvan Barb | Method of Detecting Cystic Fibrosis Associated Mutations |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
CA2571949C (en) | 2004-06-24 | 2015-05-12 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
JP2008504097A (ja) | 2004-07-01 | 2008-02-14 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ナノ粒子を含有する医薬組成物の調製 |
CA2572292A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
RU2416608C2 (ru) | 2004-08-06 | 2011-04-20 | Оцука Фармасьютикал Ко., Лтд. | Ароматическое соединение |
US20060069110A1 (en) * | 2004-09-27 | 2006-03-30 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
WO2006040520A1 (en) | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinazoline derivatives |
CA2587461A1 (en) * | 2004-11-15 | 2006-05-18 | Pfizer Products Inc. | Azabenzoxazoles for the treatment of cns disorders |
PT1856031E (pt) | 2004-12-15 | 2009-05-14 | Dompe Pha R Ma Spa Res & Mfg | Derivados de ácidos 2-arilpropiónicos e composições farmacêuticas que os contenham |
JP4790260B2 (ja) * | 2004-12-22 | 2011-10-12 | 出光興産株式会社 | アントラセン誘導体を用いた有機エレクトロルミネッセンス素子 |
US20080146612A1 (en) | 2005-01-27 | 2008-06-19 | Astrazeneca Ab | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor |
US7888374B2 (en) * | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
US20090048258A1 (en) * | 2005-02-01 | 2009-02-19 | Masaki Ogino | Amide Compound |
US8242149B2 (en) | 2005-03-11 | 2012-08-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
EP1871762A2 (en) * | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
RU2007142336A (ru) | 2005-04-19 | 2009-05-27 | Байер Фармасьютикалс Корпорейшн (US) | Арилалкилзамещенные производные кислот и их применение |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
US8822451B2 (en) | 2005-05-24 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2006130403A1 (en) | 2005-06-02 | 2006-12-07 | Bayer Cropscience Ag | Phenylalkyl substituted heteroaryl devivatives |
WO2006136829A2 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Pyrazole derivatives and their use as pka and pkb modulators |
ES2367844T3 (es) | 2005-08-11 | 2011-11-10 | Vertex Pharmaceuticals, Inc. | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística. |
MX2008002019A (es) | 2005-08-11 | 2008-04-16 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
TWI378101B (en) | 2005-09-09 | 2012-12-01 | Glaxosmithkline Llc | Pyridine derivatives and their use in the treatment of psychotic disorders |
ES2335922T3 (es) | 2005-09-23 | 2010-04-06 | F.Hoffmann-La Roche Ag | Nueva formulacion de dosificacion. |
CN101312722A (zh) | 2005-10-06 | 2008-11-26 | 沃泰克斯药物股份有限公司 | Atp-结合***转运蛋白的调控剂 |
CN103382176A (zh) | 2005-10-19 | 2013-11-06 | 格吕伦塔尔有限公司 | 新颖的辣椒素受体配体和它们用于生产药物的用途 |
US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合***转运蛋白的杂环调控剂 |
WO2007054480A1 (en) * | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
JP5103403B2 (ja) | 2005-12-05 | 2012-12-19 | スミスクライン ビーチャム コーポレーション | 2−ピリミジニルピラゾロピリジンErbBキナーゼ阻害剤 |
JP2009521504A (ja) * | 2005-12-22 | 2009-06-04 | スミスクライン・ビーチャム・コーポレイション | Akt活性阻害剤 |
AU2006331614A1 (en) | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of ABC transporters |
AU2006331565A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in CFTR assays and methods therewith |
HUE049976T2 (hu) | 2005-12-28 | 2020-11-30 | Vertex Pharma | N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói |
US7691902B2 (en) | 2005-12-28 | 2010-04-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7776905B2 (en) | 2006-04-07 | 2010-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
ATE534383T1 (de) | 2006-05-12 | 2011-12-15 | Vertex Pharma | Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
MX2009004702A (es) | 2006-11-03 | 2009-06-19 | Vertex Pharma | Derivados de azaindol como moduladores del regulador de conductancia de transmembrana de fibrosis quistica. |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
BRPI0719345A2 (pt) | 2006-11-27 | 2014-03-18 | Novartis Ag | Di-hidroimidazóis substituídos e seu uso no tratamento de tumores. |
US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
CA2688004C (en) | 2007-05-25 | 2016-07-05 | Vertex Pharmaceuticals Incorporated | Thienopyridone compounds for use as modulators of cystic fibrosis transmembrane conductance regulator |
US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
ES2578735T3 (es) | 2007-08-24 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística |
DE102007042754A1 (de) * | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
US8163772B2 (en) | 2007-09-14 | 2012-04-24 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxypheny1]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CA2699382C (en) | 2007-09-14 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
FR2921657A1 (fr) | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
SI2578571T1 (sl) | 2007-11-16 | 2016-01-29 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto |
DK2639223T3 (en) | 2007-12-07 | 2017-06-19 | Vertex Pharma | Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids |
ES2790830T3 (es) | 2007-12-07 | 2020-10-29 | Vertex Pharma | Formas solidas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
UA95199C2 (en) | 2007-12-07 | 2011-07-11 | Вертекс Фармасьютикалз Инкорпорейтед | Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
ES2422741T3 (es) | 2007-12-13 | 2013-09-13 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
NZ703814A (en) | 2008-02-28 | 2016-06-24 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
CN101981011B (zh) | 2008-03-31 | 2014-05-07 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的吡啶基衍生物 |
GB0813709D0 (en) | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
JP5575768B2 (ja) | 2008-08-13 | 2014-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | 薬学的組成物およびその投与 |
CN102164587A (zh) | 2008-09-29 | 2011-08-24 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元 |
PL2349263T3 (pl) | 2008-10-23 | 2014-11-28 | Vertex Pharma | Modulatory mukowiscydozowego regulatora przewodnictwa przezbłonowego |
US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
PT2358680E (pt) | 2008-10-23 | 2013-05-14 | Vertex Pharma | Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida |
EP2358721B1 (en) | 2008-10-23 | 2014-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
KR20160013251A (ko) | 2008-11-06 | 2016-02-03 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송자의 조절자 |
US8367660B2 (en) | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
DK2408749T3 (en) | 2009-03-20 | 2018-08-13 | Vertex Pharma | CYSTIC FIBROSE TRANSMEMBRAN CONDUCTOR CONTROLLER MODULATORS |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
DK2427166T3 (da) | 2009-05-07 | 2014-01-27 | Gea Pharma Systems Ltd | Tabletfremstillingsmodul og fremgangsmåde til kontinuerlig fremstilling af tabletter |
US8404865B2 (en) | 2009-09-17 | 2013-03-26 | Vertex Pharmaceuticals | Process for preparing azabicyclic compounds |
EP2490687A1 (en) | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
BR112012009584A2 (pt) | 2009-10-23 | 2019-09-24 | Vertex Pharma | formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluorometil)fenil)-4-oxo-5-(trifluorometil)-1,4-di-hidroquinolina-3-carboxamida |
JP5789611B2 (ja) | 2009-10-23 | 2015-10-07 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを調製するためのプロセス |
CA2792207A1 (en) | 2010-03-19 | 2011-09-22 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
RU2573830C2 (ru) | 2010-03-25 | 2016-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | ТВЕРДЫЕ ФОРМЫ (R)-1-(2,2-ДИФТОРБЕНЗО[d][1,3]ДИОКСОЛ-5-ИЛ)-N-(2,3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА |
NZ708598A (en) | 2010-04-07 | 2017-05-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d](1,3)dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
TWI549950B (zh) | 2010-04-07 | 2016-09-21 | 維泰克斯製藥公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧雜環戊烯-5-基)環丙烷甲醯胺基)-3-甲基吡啶-2-基)苯甲酸之固體形式 |
EP3045452A1 (en) | 2010-04-22 | 2016-07-20 | Vertex Pharmaceuticals Inc. | Process of producing cycloalkylcarboxamido-indole compounds |
WO2011133951A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
AU2011242454A1 (en) | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
AU2011242457A1 (en) | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
AR081920A1 (es) | 2010-05-20 | 2012-10-31 | Vertex Pharma | Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica |
AU2011255237A1 (en) | 2010-05-20 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
NZ606805A (en) | 2010-08-23 | 2015-03-27 | Vertex Pharma | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
EP2608775A2 (en) | 2010-08-27 | 2013-07-03 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
CA2853299A1 (en) | 2011-11-02 | 2013-05-10 | Vertex Pharmaceuticals Incorporated | Use of (n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) for treating cftr mediated diseases |
IN2014KN00885A (pt) | 2011-11-08 | 2015-10-02 | Vertex Pharma | |
US20140127901A1 (en) | 2012-11-08 | 2014-05-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Low-k damage free integration scheme for copper interconnects |
CN104168890A (zh) | 2012-01-25 | 2014-11-26 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的制剂 |
MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
AU2013270681A1 (en) | 2012-06-08 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of CFTR -mediated disorders |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
SI2914248T2 (sl) | 2012-11-02 | 2023-12-29 | Vertex Pharmaceuticals Incorporated, | Farmacevtski sestavki za zdravljenje bolezni, pri katerih posreduje CFTR |
US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
LT3925607T (lt) | 2014-04-15 | 2023-11-27 | Vertex Pharmaceuticals Incorporated | Farmacinė kompozicija, skirta gydyti ligas, kurias nulemia cistinės fibrozės transmembraninio laidumo reguliatorius |
WO2016057572A1 (en) | 2014-10-06 | 2016-04-14 | Mark Thomas Miller | Modulators of cystic fibrosis transmembrane conductance regulator |
JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
WO2016086136A1 (en) | 2014-11-26 | 2016-06-02 | Catabasis Pharmaceuticals, Inc. | Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders |
CA2969587A1 (en) | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
WO2016123028A1 (en) | 2015-01-26 | 2016-08-04 | Rigel Pharmaceuticals, Inc. | Tetrazolones as carboxylic acid bioisosteres |
TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
-
2008
- 2008-12-04 DK DK12196511.5T patent/DK2639223T3/en active
- 2008-12-04 PL PL08859582T patent/PL2231606T3/pl unknown
- 2008-12-04 SI SI200831820A patent/SI2639223T1/sl unknown
- 2008-12-04 ES ES12196502.4T patent/ES2604178T3/es active Active
- 2008-12-04 WO PCT/US2008/085458 patent/WO2009076142A2/en active Application Filing
- 2008-12-04 ES ES12196539.6T patent/ES2604555T3/es active Active
- 2008-12-04 PT PT121965024T patent/PT2639222T/pt unknown
- 2008-12-04 HU HUE12196539A patent/HUE029775T2/en unknown
- 2008-12-04 PT PT88595822T patent/PT2231606E/pt unknown
- 2008-12-04 DK DK12196539.6T patent/DK2639224T3/en active
- 2008-12-04 SI SI200831706A patent/SI2639222T1/sl unknown
- 2008-12-04 PL PL12196539T patent/PL2639224T3/pl unknown
- 2008-12-04 LT LTEP12196511.5T patent/LT2639223T/lt unknown
- 2008-12-04 US US12/327,915 patent/US8124781B2/en active Active
- 2008-12-04 ES ES12196511.5T patent/ES2625957T3/es active Active
- 2008-12-04 LT LTEP12196539.6T patent/LT2639224T/lt unknown
- 2008-12-04 DK DK08859582.2T patent/DK2231606T3/da active
- 2008-12-04 CA CA2707494A patent/CA2707494C/en active Active
- 2008-12-04 CN CN200880124151.0A patent/CN101910134B/zh active Active
- 2008-12-04 RS RS20160828A patent/RS55360B1/sr unknown
- 2008-12-04 DK DK12196502.4T patent/DK2639222T3/en active
- 2008-12-04 CA CA2989620A patent/CA2989620C/en active Active
- 2008-12-04 PT PT121965396T patent/PT2639224T/pt unknown
- 2008-12-04 EP EP12196511.5A patent/EP2639223B1/en active Active
- 2008-12-04 EP EP12196502.4A patent/EP2639222B1/en active Active
- 2008-12-04 HU HUE12196511A patent/HUE032268T2/en unknown
- 2008-12-04 RS RS20130184A patent/RS52759B/en unknown
- 2008-12-04 MX MX2013009269A patent/MX364935B/es unknown
- 2008-12-04 KR KR1020157014536A patent/KR20150066608A/ko not_active Application Discontinuation
- 2008-12-04 SI SI200830952T patent/SI2231606T1/sl unknown
- 2008-12-04 PL PL12196511T patent/PL2639223T3/pl unknown
- 2008-12-04 ES ES08859582T patent/ES2406940T3/es active Active
- 2008-12-04 MX MX2013009270A patent/MX365732B/es unknown
- 2008-12-04 NZ NZ612635A patent/NZ612635A/en unknown
- 2008-12-04 BR BRPI0820902-2A patent/BRPI0820902A2/pt not_active Application Discontinuation
- 2008-12-04 JP JP2010537039A patent/JP5702149B2/ja active Active
- 2008-12-04 CN CN201410048078.0A patent/CN103864678B/zh active Active
- 2008-12-04 PL PL12196502T patent/PL2639222T3/pl unknown
- 2008-12-04 EP EP08859582A patent/EP2231606B1/en active Active
- 2008-12-04 RS RS20170588A patent/RS56083B1/sr unknown
- 2008-12-04 LT LTEP12196502.4T patent/LT2639222T/lt unknown
- 2008-12-04 RS RS20160784A patent/RS55298B1/sr unknown
- 2008-12-04 NZ NZ585794A patent/NZ585794A/en unknown
- 2008-12-04 PT PT121965115T patent/PT2639223T/pt unknown
- 2008-12-04 KR KR1020167009109A patent/KR101674404B1/ko active IP Right Grant
- 2008-12-04 CA CA3147290A patent/CA3147290A1/en active Pending
- 2008-12-04 EP EP12196539.6A patent/EP2639224B1/en active Active
- 2008-12-04 HU HUE12196502A patent/HUE031871T2/en unknown
- 2008-12-04 KR KR1020107015002A patent/KR101612009B1/ko active IP Right Grant
- 2008-12-04 AU AU2008335440A patent/AU2008335440B2/en active Active
- 2008-12-04 EA EA201070700A patent/EA201070700A1/ru unknown
- 2008-12-04 NZ NZ599684A patent/NZ599684A/xx unknown
- 2008-12-04 SI SI200831715A patent/SI2639224T1/sl unknown
- 2008-12-04 MX MX2013009273A patent/MX364936B/es unknown
- 2008-12-04 MX MX2010006183A patent/MX2010006183A/es active IP Right Grant
-
2010
- 2010-05-21 ZA ZA2010/03624A patent/ZA201003624B/en unknown
- 2010-06-06 IL IL206205A patent/IL206205A/en active IP Right Grant
- 2010-06-16 CL CL2010000631A patent/CL2010000631A1/es unknown
-
2011
- 2011-01-14 HK HK11100362.7A patent/HK1146820A1/xx unknown
-
2012
- 2012-01-17 US US13/351,573 patent/US8592602B2/en active Active
-
2013
- 2013-05-10 HR HRP20130418AT patent/HRP20130418T1/hr unknown
- 2013-05-13 CY CY20131100380T patent/CY1113985T1/el unknown
- 2013-05-19 IL IL226410A patent/IL226410A/en active IP Right Grant
- 2013-05-19 IL IL226412A patent/IL226412A/en active IP Right Grant
- 2013-05-19 IL IL226411A patent/IL226411A/en active IP Right Grant
- 2013-10-23 US US14/061,004 patent/US9321725B2/en active Active
- 2013-12-06 JP JP2013252770A patent/JP5797726B2/ja active Active
-
2014
- 2014-11-27 JP JP2014239562A patent/JP2015044854A/ja active Pending
- 2014-12-10 HK HK14112410.1A patent/HK1199019A1/xx unknown
-
2015
- 2015-11-16 JP JP2015223684A patent/JP2016026233A/ja active Pending
-
2016
- 2016-03-17 US US15/073,591 patent/US9776968B2/en active Active
- 2016-11-21 HR HRP20161543TT patent/HRP20161543T1/hr unknown
- 2016-11-22 CY CY20161101202T patent/CY1118332T1/el unknown
- 2016-11-24 HR HRP20161572TT patent/HRP20161572T1/hr unknown
- 2016-11-30 CY CY20161101240T patent/CY1118310T1/el unknown
-
2017
- 2017-06-05 HR HRP20170851TT patent/HRP20170851T1/hr unknown
- 2017-06-15 CY CY20171100629T patent/CY1118992T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201003624B (en) | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids | |
EP2303885A4 (en) | PROCESS FOR PRODUCING BICYCLOANILINE DERIVATIVES | |
PL2237677T3 (pl) | Sposób wytwarzania materiału pochodzącego z kakao | |
LT1989165T (lt) | Karboksirūgšties gamybos būdas | |
EP2357164A4 (en) | PROCESS FOR THE PRODUCTION OF A -SUBSTITUTED ESTER | |
ZA201201237B (en) | Process for preparing decanecarboxylic acids | |
EP2128122A4 (en) | PROCESS FOR PREPARING A CARBONIC ACID CHLORIDE | |
EP2330184A4 (en) | METHOD FOR PRODUCING A USEFUL SUBSTANCE | |
EP2246322A4 (en) | PROCESS FOR PREPARING ALPHA-FLUORO-BETA-AMINO ACIDS | |
EP2383275A4 (en) | PROCESS FOR SYNTHESIZING O-DIPHENYLPHOSPHINOBENZOIC ACID | |
HUP0700461A2 (en) | Process for producing 9alpha-hydroxy-steroids | |
HU0700411D0 (en) | Process for producing quetiapin | |
GB0813909D0 (en) | Esterification process | |
EP2332902A4 (en) | PROCESS FOR PRODUCING A -TRIFLUOROMETHYL-ESTER, -INSATURATED | |
IL194977A0 (en) | Process for preparing gabapentin | |
EP2327685A4 (en) | PROCESS FOR PRODUCTION OF ACID -AMINATED -TRIFLUOROMETHYL- -SUBSTITUTED | |
HU0800467D0 (en) | Process for producing n-methyl-aryloxy-propaneamin derivatives | |
HUP0800235A2 (en) | Process for producing products comprising oil-sed | |
IL195741A0 (en) | Process for preparing gabapentin |